Skip to main content
. 2022 Aug 27;24(10):1892–1901. doi: 10.1002/ejhf.2652

Figure 1.

EJHF-2652-FIG-0001-c

Effect of dapagliflozin versus placebo on primary and secondary endpoints by baseline New York Heart Association (NYHA) functional class. CI, confidence interval; CV, cardiovascular; HF, heart failure.